Share Article
Dealing with a Prostate Cancer Diagnosis

UsToo and Dr. Daniel Fried Present Webcast and Q and A on Prostate Cancer Radiation Therapy

UsToo and Dr. Daniel Fried Present Webcast and Q and A on Prostate Cancer Radiation Therapy

Watch Now

*Please Note – In the video below, “Augmenix” is mentioned several times. Boston Scientific acquired Augmenix on October 16th, 2018.

In the fall of 2017, Us TOO International held a live webcast on radiation therapy for their prostate cancer support group meeting. The event, held in Greenville, SC, was sponsored by Augmenix, INC. (acquired by Boston Scientific in 2018).

Dr. Daniel Fried, a radiation oncologist from Gibbs Cancer Center and Research Institute, was the speaker at the meeting, presenting on his experience with SpaceOAR Hydrogel as well as answering questions from the audience about prostate cancer treatment and diagnosis.

Us TOO’s mission is to provide hope and improvement to the lives of prostate cancer patients as well as their families and friends through support, education, and advocacy/awareness.

Dr. Daniel Fried discusses radiation therapy for Prostate Cancer at an UsToo Support group meeting held in Greenville, SC
Dr. Fried addresses questions from the audience
The audience had some great questions for Dr. Fried.
Johnny Payne, Leader of the Us TOO support group in Greenville, SC

To find a local Us TOO International support group, visit:

Caution: U.S. Federal law restricts this device to sale by or on the order of a physician.

CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with each device. Information for use only in countries with applicable health authority registrations. This material not intended for use in France. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. Please check availability with your local sales representative or customer service.

Results from case studies are not necessarily predictive of results in other cases. Results in other cases may vary.

SpaceOAR is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer and in creating this space it is the intent of SpaceOAR Hydrogel to reduce the radiation dose delivered to the anterior rectum.

As with any medical treatment, there are some risks involved with the use of SpaceOAR Hydrogel. Potential complications associated with SpaceOAR Hydrogel include, but are not limited to: pain associated with SpaceOAR Hydrogel injection; pain or discomfort associated with SpaceOAR Hydrogel; needle penetration of the bladder, prostate, rectal wall, rectum or urethra; injection of SpaceOAR Hydrogel into the bladder, prostate, rectal wall, rectum or urethra; local inflammatory reactions; infection; injection of air, fluid or SpaceOAR Hydrogel intravascularly; urinary retention; rectal mucosal damage, ulcers, necrosis; bleeding; and rectal urgency. Please talk to your doctor about the risks and benefits associated with SpaceOAR Hydrogel.

All trademarks are the property of their respective owners. URO-777307-AA AUG 2020